CDK 4-6 Inhibitors in Breast Cancer
The programme is designed to offer an overview of research activities in this area and review the current status and future prospects of CDK4-6 inhibitors in breast cancer.
CDK 4-6 Inhibitors in Breast Cancer
Chair: Giuseppe Curigliano
Speakers: Stephen Johnston, Monica Arnedos, Hope Rugo
*The ESMO Webinar Series is freely available to all healthcare professionals working in Oncology.
Programme
- Welcome and Introduction, Giuseppe Curigliano, MD, PhD, University of Milano, Istituto Europeo di Oncologia, Milan, Italy
- Maximising Outcomes in Patients with HR+/HER2- Metastatic Breast Cancer: Expert Insights Into the Latest Data, Stephen Johnston, MA, PhD, FRCP, The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, London, UK
- CDK 4-6 Inhibitors in Clinical Practice: Expert Perspectives and Recommendations, Monica Arnedos, MD, Institut Gustave Roussy, Villejuif, France
- CDK 4-6 Inhibitors in Early Breast Cancer: Ongoing Trials and Definition of High Risk Population, Hope Rugo, MD, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, US
- Q & A and Closing Remarks, Giuseppe Curigliano, MD, PhD, University of Milano, Istituto Europeo di Oncologia, Milan, Italy
Learning objectives
- To provide an update on the clinical role of CDK 4-6 inhibitors in the management of breast cancer
- To contextualise the latest data with CDK 4-6 inhibitors and implications on treatment outcomes in patients with HR+/HER2- metastatic breast cancer
- To provide an update on research efforts with CDK 4-6 inhibitors in early breast cancer
*The ESMO Webinar Series is freely available to all healthcare professionals working in Oncology.
